Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryptococcus neoformans and Cryptococcus gattii, the Etiologic Agents of Cryptococcosis

(2014) K. J. Kwon-Chung et al.   Cold Spring Harbor Perspectives in Medicine

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL

(2013) Gerardo Ferrer et al.   BRITISH JOURNAL OF HAEMATOLOGY

X-Linked Immunodeficient Mice Exhibit Enhanced Susceptibility to Cryptococcus neoformans Infection

(2013) W. A. Szymczak et al.   mBio

Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia

(2012) Dimitrios P. Kontoyiannis et al.   LEUKEMIA & LYMPHOMA

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

(2010) H Grant et al.   LEUKEMIA

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

(2009) Benjamin J Park et al.   AIDS

Cryptococcus neoformans: Morphogenesis, infection, and evolution

(2009) Xiaorong Lin   INFECTION GENETICS AND EVOLUTION

Disease-Specific Complications of Chronic Lymphocytic Leukemia

(2008) C. Dearden   Hematology-American Society of Hematology Education Program